Exclusion
LQT08-hiPSC
Exclude from clean allogeneic source-line shortlist.
Disease-model or disease-related mutation evidence is present.
StatusExclusion
Source-line readiness across catalogue coverage, evidence gaps, exclusion overrides, and HLA computability.
Seeded source-line records
Still eligible for review
Override clean QC signals
Reviewed matrix cells
Allele-ready lines
Rights, CoA, GMP gaps
KSCBi005-A
Needs source verification before readiness scoring.
KSCBi018-A
Needs source verification before readiness scoring.
KSCBi019-A
Needs source verification before readiness scoring.
KSCBi020-A
Needs source verification before readiness scoring.
KSCBi021-A
Needs source verification before readiness scoring.
KSCBi027-A
Needs source verification before readiness scoring.
KSCBi028-A
Needs source verification before readiness scoring.
Cell viability
KSCBi005-A
STR authentication
KSCBi005-A
Mycoplasma PCR
KSCBi005-A
Microbial contamination
KSCBi005-A
Viral contamination
KSCBi005-A
Cell attachment / morphology
KSCBi005-A
Karyotype G-banding
KSCBi005-A
Exclusion
Exclude from clean allogeneic source-line shortlist.
Disease-model or disease-related mutation evidence is present.
Exclusion
Exclude from clean allogeneic source-line shortlist.
Genetic modification is present or reported for this line.
Next evidence
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
Rights review
Verify donor consent and commercial-use rights.
Commercial-use rights are a blocker for source-line selection.
Next evidence
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
Rights review
Verify donor consent and commercial-use rights.
Commercial-use rights are a blocker for source-line selection.
Next evidence
Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim.
Population-fit readiness cannot be computed without allele-level HLA typing.
Rights review
Verify donor consent and commercial-use rights.
Commercial-use rights are a blocker for source-line selection.
| Priority | Line | Type | Recommendation | Rationale | Status |
|---|---|---|---|---|---|
| P0 | LQT08-hiPSC | Exclusion | Exclude from clean allogeneic source-line shortlist. | Disease-model or disease-related mutation evidence is present. | Exclusion |
| P0 | PB01-EiPS21-EGFP04 | Exclusion | Exclude from clean allogeneic source-line shortlist. | Genetic modification is present or reported for this line. | Exclusion |
| P1 | KSCBi005-A | Next evidence | Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim. | Population-fit readiness cannot be computed without allele-level HLA typing. | Open |
| P1 | KSCBi005-A | Rights review | Verify donor consent and commercial-use rights. | Commercial-use rights are a blocker for source-line selection. | Open |
| P1 | KSCBi018-A | Next evidence | Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim. | Population-fit readiness cannot be computed without allele-level HLA typing. | Open |
| P1 | KSCBi018-A | Rights review | Verify donor consent and commercial-use rights. | Commercial-use rights are a blocker for source-line selection. | Open |
| P1 | KSCBi019-A | Next evidence | Obtain high-resolution HLA-A/B/C/DRB1/DQB1/DPB1 typing before population-fit claim. | Population-fit readiness cannot be computed without allele-level HLA typing. | Open |
| P1 | KSCBi019-A | Rights review | Verify donor consent and commercial-use rights. | Commercial-use rights are a blocker for source-line selection. | Open |
McClintock converts linked evidence into line-level decisions. A line can look green on viability, STR, mycoplasma, pluripotency, and karyotype while still being excluded because it is reporter-modified, disease-model derived, abnormal, or commercially blocked.